[Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases].

Autor:	Robert PY; Service d'Ophtalmologie, C.H.U. Dupuytren, Limoges., Delbosc B, Preux PM, Monnot PH, Drouet M, Peyronnet P, Adenis JP
Jazyk:	francouzština
Zdroj:	Journal francais d'ophtalmologie [J Fr Ophtalmol] 1997; Vol. 20 (7), pp. 507-14.
Abstrakt:	Purpose: Evaluation of cyclosporin-A in prevention of immune reaction in high-risk penetrating keratoplasties. Material and Methods: Cyclosporin A was given to 45 corneal allograft recipients, 5 mg/kg/j (cyclosporinemy between 100 and 150 ng/l), for three months following surgery. 45 controls have undergone penetrating keratoplasty during the same period. Mean follow-up was respectively 431 days and 402 days. Survival was analysed according to Kaplan-Meier's method, and then using Cox model. Results: The significant predictive factors were the number of neovascularized quadrants, and the graft diameter. No significant effect of cyclosporin is evidenced. Side effects are marginal. Conclusion: Three hypothesis may explain the absence of prognosis improvement in the Cyclosporin A treated group: insufficient dose or duration of treatment, individual risk factors that prevents correct pairing, or corneal-specific immunological mechanisms.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu